US Stock MarketDetailed Quotes
GTHX G1 Therapeutics
- 7.150
- 0.0000.00%
Close Sep 17 16:00 ET
377.22MMarket Cap-8313P/E (TTM)
0.000High0.000Low0Volume0.000Open7.150Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)52.76MShares7.19052wk High15.34P/B279.70MFloat Cap1.08052wk Low--Dividend TTM39.12MShs Float69.570Historical High--Div YieldTTM0.00%Amplitude1.080Historical Low--Avg Price1Lot Size
G1 Therapeutics Stock Forum
Sign in to post a comment
$G1 Therapeutics (GTHX.US)$ Reuters· 3 mins ago
G1 Therapeutics Inc - Pharmacosmos to Acquire G1 Therapeutics for $405 Million
G1 Therapeutics Inc: G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Mln
G1 Therapeutics Inc - Pharmacosmos to Acquire G1 Therapeutics for $405 Million
G1 Therapeutics Inc: G1's Shareholders to Receive U.S. $7.15 per Share in Cash for a Total Equity Value of Approximately $405 Mln
1
4
$Humacyte (HUMA.US)$ anything approaching home run (>100%) in a month near 1 year resistance above or below in very bullish characteristics, worth keeping in watchlist
$G1 Therapeutics (GTHX.US)$ : To Wind Down Phase 3 Preserve 2 Trial, Discontinue Anticipated Hiring of Staff and Investment for a 1L Tnbc Indication
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Do u think still good to buy some and hold fr long term? (I rmb they have one product ald commersialize right)$G1 Therapeutics (GTHX.US)$ Meaningful Improvement in Overall Survival (Os) and Tolerability Observed in Patients Receiving Trilaciclib in Combination With a Trop2 Antibody-Drug Conjugate (ADC)! Results Indicate Use of Trilaciclib With Trop2 ADC May Be Associated With Improved Median Os Compared to Historical Data for ADC Alone! On-Target Effect of Trilaciclib Cuts Rates of Multiple Many Adverse Events Associated With Trop2 ADC
$G1 Therapeutics (GTHX.US)$ G1 Therapeutics And Deimos Biosciences Announced A Global Licensing Agreement (Excluding The Asia-pacific Region) For Lerociclib For Radioprotective Uses; G1 Is Expected To Receive 10% Of Deimos Biosciences' Shares In Addition To A 20% Sales-based Royalty
$United Therapeutics (UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Liquidia (LQDA.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$MorphoSys (MOR.US)$ Phase 3
$Immunocore (IMCR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$AstraZeneca (AZN.US)$ Phase 3
$Capricor Therapeutics (CAPR.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3 ...
14
1
$G1 Therapeutics (GTHX.US)$ game time
4
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Uptrendpls : How to know early for this kind stock for raise? Hehe
Trytosaveabit OP Uptrendpls : Sometimes you just can’t know! You might have a hunch so you buy and hold to see ifn you are right. Hehehe
Uptrendpls Trytosaveabit OP : Nvm, keep following you for the right. Hehe
Boxman :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")